Anti-Inflammatory Effects of Hyperoside in Human Endothelial Cells and in Mice

Inflammation

Volumn 38, Issue 2, 2015, Pages 784-799

  Ku, Sae Kwang ^a   Zhou, Wei ^b   Lee, Wonhwa ^c,d   Han, Min Su ^e   Na, MinKyun ^b   Bae, Jong Sup ^c  

^a Daegu Haany University   (South Korea)

^b Chungnam National University   (South Korea)

^c Kyungpook National University   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e Daegu Fatima Hospital   (South Korea)

Author keywords

HMGB1; hyperoside; sepsis; vascular inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; HYPERIN; PLANT EXTRACT; QUERCETIN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; HUMAN; INFLAMMATION; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PHYSIOLOGY; PLANT LEAF; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; PLANT LEAVES; QUERCETIN; TREATMENT OUTCOME;

EID: 84939895013     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9989-8     Document Type: Article

References (65)

1. Russell, J.A., and K.R. Walley. 2013. Update in sepsis 2012. American Journal of Respiratory and Critical Care Medicine 187: 1303–1307.
2. Lotze, M.T., and K.J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nature Reviews Immunology 5: 331–342.
3. Bae, J.S. 2012. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Archives of Pharmacal Research 35: 1511–1523.
4. Wang, H., O. Bloom, M. Zhang, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.
5. Hori, O., J. Brett, T. Slattery, et al. 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. Journal of Biological Chemistry 270: 25752–25761.
6. Park, J.S., D. Svetkauskaite, Q. He, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.
7. Bae, J.S., and A.R. Rezaie. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952–3959.
8. Yang, H., M. Ochani, J. Li, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.
9. Mossier, L.O., B.V. Zlokovic, and J.H. Griffin. 2007. The cytoprotective protein C pathway. Blood 109: 3161–3172.
10. Xu, J., D. Qu, N.L. Esmon, and C.T. Esmon. 2000. Metalloproteolytic release of endothelial cell protein C receptor. Journal of Biological Chemistry 275: 6038–6044.
11. Kurosawa, S., D.J. Stearns-Kurosawa, C.W. Carson, A. D’Angelo, P. Della Valle, and C.T. Esmon. 1998. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91: 725–727.
12. Persson, P.B., and A.B.. Persson. 2012. Age your garlic for longevity! Acta Physiologica (Oxford, England) 205: 1–2.
13. Middleton Jr., E., and G. Drzewiecki. 1984. Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochemical Pharmacology 33: 3333–3338.
14. Mukaida, N. 2000. Interleukin-8: An expanding universe beyond neutrophil chemotaxis and activation. International Journal of Hematology 72: 391–398.
15. Hirano, T., S. Higa, J. Arimitsu, et al. 2006. Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochemical and Biophysical Research Communications 340: 1–7.
16. Zou, Y., Y. Lu, and D. Wei. 2004. Antioxidant activity of a flavonoid-rich extract of Hypericum perforatum L. in vitro. Journal of Agricultural and Food Chemistry 52: 5032–5039.
17. Zhou, W., J. Oh, W. Li, D.W. Kim, S.H. Lee, and M. Na. 2013. Phytochemical studies of Korean endangered plants: A new flavone from Rhododendron brachycarpum G Don. Bulletin of the Korean Chemical Society 34: 2535–2538.
18. Li, H.B., X. Yi, J.M. Gao, X.X. Ying, H.Q. Guan, and J.C. Li. 2008. The mechanism of hyperoside protection of ECV-304 cells against tert-butyl hydroperoxide-induced injury. Pharmacology 82: 105–113.
19. Verma, N., G. Amresh, P.K. Sahu, N. Mishra, V. Rao Ch, and A.P. Singh. 2013. Pharmacological evaluation of hyperin for antihyperglycemic activity and effect on lipid profile in diabetic rats. Indian Journal of Experimental Biology 51: 65–72.
20. Li, F.R., F.X. Yu, S.T. Yao, Y.H. Si, W. Zhang, and L.L. Gao. 2012. Hyperin extracted from Manchurian rhododendron leaf induces apoptosis in human endometrial cancer cells through a mitochondrial pathway. Asian Pacific Journal of Cancer Prevention 13: 3653–3656.
21. Kim, S.J., J.Y. Um, and J.Y. Lee. 2011. Anti-inflammatory activity of hyperoside through the suppression of nuclear factor-kappaB activation in mouse peritoneal macrophages. American Journal of Chinese Medicine 39: 171–181.
22. Li, Z.L., J. Hu, Y.L. Li, et al. 2013. The effect of hyperoside on the functional recovery of the ischemic/reperfused isolated rat heart: Potential involvement of the extracellular signal-regulated kinase 1/2 signaling pathway. Free Radical Biology and Medicine 57: 132–140.
23. Ku, S.K., T.H. Kim, S. Lee, S.M. Kim, and J.S. Bae. 2012. Antithrombotic and profibrinolytic activities of isorhamnetin-3-O-galactoside and hyperoside. Food and Chemical Toxicology 53C: 197–204.
24. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Archives of Pharmacal Research 36: 1160–1165.
25. Bae, J.S., and A.R. Rezaie. 2013. Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Reports 46: 544–549.
26. Ku, S.K., E.J. Yang, K.S. Song, and J.S. Bae. 2013. Rosmarinic acid down-regulates endothelial protein C receptor shedding in vitro and in vivo. Food and Chemical Toxicology 59: 311–315.
27. Kim, T.H., S.K. Ku, I.C. Lee, and J.S. Bae. 2012. Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Reports 45: 200–205.
28. Bae, J.S., L. Yang, C. Manithody, and A.R. Rezaie. 2007. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909–3916.
29. Bae, J.S., W. Lee, and A.R. Rezaie. 2012. Polyphosphate elicits proinflammatory responses that are counteracted by activated protein C in both cellular and animal models. Journal of Thrombosis and Haemostasis.
30. Valerio, D.A., T.M. Cunha, N.S. Arakawa, et al. 2007. Anti-inflammatory and analgesic effects of the sesquiterpene lactone budlein A in mice: Inhibition of cytokine production-dependent mechanism. European Journal of Pharmacology 562: 155–163.
31. Lee, W., S.K. Ku, J.A. Kim, T. Lee, and J.S. Bae. 2013. Inhibitory effects of epi-sesamin on HMGB1-induced vascular barrier disruptive responses in vitro and in vivo. Toxicology and Applied Pharmacology 267: 201–208.
32. Wang, H., H. Liao, M. Ochani, et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine 10: 1216–1221.
33. Jang, G.U.J., S.U.C. Choi, and K.R.L. Lee. 2005. Cytotoxic constituents of Rhododendron brachycarpum. Yakhak Hoeji 49: 244–248.
34. Liu, Z., X. Tao, C. Zhang, Y. Lu, and D. Wei. 2005. Protective effects of hyperoside (quercetin-3-o-galactoside) to PC12 cells against cytotoxicity induced by hydrogen peroxide and tert-butyl hydroperoxide. Biomedicine and Pharmacotherapy 59: 481–490.
35. Yoo, H., S.K. Ku, Y.D. Baek, and J.S. Bae. 2013. Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo. Inflammation Research
36. Mullins, G.E., J. Sunden-Cullberg, A.S. Johansson, et al. 2004. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 60: 566–573.
37. Buras, J.A., B. Holzmann, and M. Sitkovsky. 2005. Animal models of sepsis: Setting the stage. Nature Reviews Drug Discovery 4: 854–865.
38. Sama, A.E., J. D’Amore, M.F. Ward, G. Chen, and H. Wang. 2004. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Academic Emergency Medicine 11: 867–873.
39. Berman, R.S., J.D. Frew, and W. Martin. 1993. Endotoxin-induced arterial endothelial barrier dysfunction assessed by an in vitro model. British Journal of Pharmacology 110: 1282–1284.
40. Goldblum, S.E., X. Ding, T.W. Brann, and J. Campbell-Washington. 1993. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: Concurrent F-actin depolymerization and new actin synthesis. Journal of Cellular Physiology 157: 13–23.
41. Wolfson, R.K., E.T. Chiang, and J.G. Garcia. 2011. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvascular Research 81: 189–197.
42. Yang, H., H. Wang, C.J. Czura, and K.J. Tracey. 2005. The cytokine activity of HMGB1. Journal of Leukocyte Biology 78: 1–8.
43. Qin, Y.H., S.M. Dai, G.S. Tang, et al. 2009. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. Journal of Immunology 183: 6244–6250.
44. Sun, C., C. Liang, Y. Ren, et al. 2009. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Research in Cardiology 104: 42–49.
45. Schnittler, H.J., S.W. Schneider, H. Raifer, et al. 2001. Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflügers Archiv 442: 675–687.
46. Friedl, J., M. Puhlmann, D.L. Bartlett, et al. 2002. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: Relationship between the procoagulant and permeability effects of TNF. Blood 100: 1334–1339.
47. Petrache, I., A. Birukova, S.I. Ramirez, J.G. Garcia, and A.D. Verin. 2003. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. American Journal of Respiratory Cell and Molecular Biology 28: 574–581.
48. Qu, D., Y. Wang, Y. Song, N.L. Esmon, and C.T. Esmon. 2006. The Ser219→Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. Journal of Thrombosis and Haemostasis 4: 229–235.
49. Qu, D., Y. Wang, N.L. Esmon, and C.T. Esmon. 2007. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. Journal of Thrombosis and Haemostasis 5: 395–402.
50. Menschikowski, M., A. Hagelgans, G. Eisenhofer, and G. Siegert. 2009. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Experimental Cell Research 315: 2673–2682.
51. Andersson, U., H. Wang, K. Palmblad, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 192: 565–570.
52. Hansson, G.K., and P. Libby. 2006. The immune response in atherosclerosis: A double-edged sword. Nature Reviews Immunology 6: 508–519.
53. Andersson, U., and K.J. Tracey. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology 29: 139–162.
54. Wang, F.P., L. Li, J. Li, J.Y. Wang, L.Y. Wang, and W. Jiang. 2013. High Mobility Group Box-1 Promotes the Proliferation and Migration of Hepatic Stellate Cells via TLR4-Dependent Signal Pathways of PI3K/Akt and JNK. Plops One 8: e64373.
55. Locker, J.M., J.S. Colladay, W.L. Alperin-Lea, T. Hammond, and A.J. Buda. 1998. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circulation Research 82: 314–320.
56. Rose, B.A., T. Force, and Y. Wang. 2010. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews 90: 1507–1546.
57. Park, J.S., F. Gamboni-Robertson, Q. He, et al. 2006. High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology - Cellular Physiology 290: C917–924.
58. Yang, H., and K.J. Tracey. 2010. Targeting HMGB1 in inflammation. Biochimica et Biophysica Acta 1799: 149–156.
59. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885–891.
60. Bhatia, M., M. He, H. Zhang, and S. Moochhala. 2009. Sepsis as a model of SIRS. Frontiers in Bioscience 14: 4703–4711.
61. Tracey, K.J., Y. Fong, D.G. Hessen, et al. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664.
62. Wichterman, K.A., A.E. Baue, and I.H. Chaudry. 1980. Sepsis and septic shock—A review of laboratory models and a proposal. Journal of Surgical Research 29: 189–201.
63. Wang, H., H. Yang, C.J. Czura, A.E. Sama, and K.J. Tracey. 2001. HMGB1 as a late mediator of lethal systemic inflammation. American Journal of Respiratory and Critical Care Medicine 164: 1768–1773.
64. Haggag, E.G., M.I.S. Abdelhady, and A.M. Kamal. 2013. Phenolic content of Ruprechtia salicifolia leaf and its immunomodulatory, anti-inflammatory, anticancer and antibacterial activity. Journal of Pharmacy Research 6: 696–703.
65. Yoo, H., S.K. Ku, Y.D. Baek, and J.S. Bae. 2014. Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo. Inflammation Research 63: 197–206.